KHA-CARI guideline: Biochemical and haematological targets: Haemoglobin concentrations in patients using erythropoietin-stimulating agents

Nephrology

Volumn 17, Issue 1, 2012, Pages 17-19

  McMahon, Lawrence P ^a   MacGinley, Robert ^b  

^a MONASH UNIVERSITY   (Australia)

^b Deakin University Medical School   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; AUSTRALIA AND NEW ZEALAND; BIOACCUMULATION; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; DISEASE CONTROL; EVIDENCE BASED PRACTICE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANEMIA; BLOOD TRANSFUSION; CHRONIC DISEASE; DISEASE MANAGEMENT; ERYTHROPOIETIN; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; REFERENCE STANDARDS; RENAL DIALYSIS; RISK ADJUSTMENT;

EID: 84855161987     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01535.x     Document Type: Review

References (11)

1. Palmer SC, Navaneethan SD, Craig JC, et al,. Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann. Intern. Med. 2010; 153: 23-33.
2. Junor BJ,. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful. Perit. Dial. Int. 1993; 13 (Suppl. 2): S535-7. (Pubitemid 23261262)
3. Raine AE,. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1988; 1: 97-100.
4. Shinaberger JH, Miller JH, Gardner PW,. Erythropoietin alert: Risks of high hematocrit hemodialysis. ASAIO Trans. 1988; 34: 179-84.
5. Boobes Y,. Pre-dialysis or post-dialysis hematocrit to monitor EPO treatment? Nephrology 1997; 3: S306.
6. Laudat K, Paulitschke M, Riedel E, et al,. Complete correction of renal anemia-no increased risk in access thrombosis or thromboembolic events in hemodialysis patients. J. Am. Soc. Nephrol. 1998; 9: 219A.
7. Strippoli GFM, Navaneethan SD, Craig JC, et al,. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst. Rev. 2006; (4): CD003967.
8. Phrommintikul A, Haas SJ, Elsik M, et al,. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007; 369: 381-8. (Pubitemid 46188479)
9. Gandra SR, Finkelstein FO, Bennett AV, et al,. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am. J. Kidney Dis. 2010; 55: 519-34.
10. Johansen KL, Finkelstein FO, Revicki DA, et al,. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am. J. Kidney Dis. 2010; 55: 535-48.
11. Clement FM, Klarenbach S, Tonelli M, et al,. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch. Intern. Med. 2009; 169: 1104-12.